# Wuhan Institute of Virology

China’s COVID Pill VV116 Shows Promise Against Deadly Nipah Virus — But Clinical and Commercial Hurdles Remain

A Wuhan Institute-led study finds that VV116, an oral antiviral developed in China for COVID-19, inhibits Nipah virus in cell cultures and improves survival in a rodent model. The result offers a potential stopgap against a pathogen with high fatality and no approved treatments, but clinical trials and regulatory approval are still required before human use. Corporate partners gave mixed responses and markets briefly rallied on the news.